IMPORTANCE: Recurrent respiratory papillomatosis (RRP) is a rare benign chronic disease of the larynx etiologically linked with the infection of low-risk human papillomavirus (HPV). Combination of surgical and immunomodulatory therapy has limited success. Possible use of prophylactic HPV vaccine that includes HPV-6 and HPV-11 antigens has been studied. OBJECTIVE: To evaluate if the HPV vaccination is associated with a lower number of recurrences requiring surgical intervention in patients with new and recurrent RRP. DESIGN, SETTING, AND PARTICIPANTS: This was a non-placebo-controlled intervention study. Enrollment data were collected from October 2011 to August 2013. The patients were followed up at 1 month, 12 months, and 5 years after the third dose of the vaccine and clinically monitored until December 31, 2018. Data were analyzed from 2019 to 2021. Altogether, 50 adults with active RRP were enrolled and followed up in referral centers. For the final outcome, follow-up data for 42 patients were available. Eight patients who did not fulfill the protocol were excluded. INTERVENTIONS: All patients received HPV vaccine as an adjuvant treatment and were clinically followed up. When RRP progression or a significant recurrent lesion was detected, surgical removal via direct laryngoscopy was indicated. No adjuvant therapy with antiviral or biological agents was used. MAIN OUTCOMES AND MEASURES: This study compared the prevaccination and postvaccination positivity for HPV-specific antibodies. The main outcome was the difference in the frequency of RRP recurrences in the prevaccination and postvaccination period. RESULTS: A total of 50 patients with RRP were enrolled (median [SD] age, 41.5 [12.3] years [range, 21-73 years]; 39 [78%] men and 11 [22%] women). After HPV vaccination, patients with previously no HPV-specific antibodies showed seroconversion, and all patients developed 100-fold higher levels of HPV vaccine type-specific antibodies compared with the prevaccination period. In patients with recurrent RRP, decreased frequency of recurrences requiring surgical treatment was present after vaccination (from 0.85 to 0.36 recurrences/y). No difference in postvaccination recurrences was found between patients with newly diagnosed and recurrent RRP. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, the frequency of RRP recurrences was significantly lower after HPV vaccination, and patients with RRP thus had a reduced burden of disease. Because no difference was detected in the frequency of recurrent postvaccination lesions in patients with new and recurrent disease, it appears that both groups showed equal benefit following HPV vaccination. These findings suggest that the earlier that patients with RRP receive HPV vaccine, the sooner they may show reduced burden of disease. TRIAL REGISTRATION: EudraCT Identifier: 2011-002667-14; ClinicalTrials.gov Identifier: NCT01375868.

Department of ENT Head and Neck Surgery Na Homolce Hospital Prague Czech Republic

Department of Genetics and Microbiology Faculty of Science BIOCEV Charles University Prague Czech Republic

Department of Mathematical Analysis and Applications of Mathematics Faculty of Science Palacky University Olomouc Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery 1st Faculty of Medicine Charles University Motol University Hospital Prague Czech Republic

Institute of Hematology and Blood Transfusion National Reference Laboratory for Papillomaviruses and Polyomaviruses Prague Czech Republic

Prague Voice Centre Medical Healthcom Prague Czech Republic

Zobrazit více v PubMed

Derkay CS, Bluher AE. Recurrent respiratory papillomatosis: update 2018. Curr Opin Otolaryngol Head Neck Surg. 2018;26(6):421-425. doi:10.1097/MOO.0000000000000490 PubMed DOI

Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg. 2008;16(6):536-542. doi:10.1097/MOO.0b013e328316930e PubMed DOI

Buchinsky FJ, Valentino WL, Ruszkay N, et al. . Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis. PLoS One. 2019;14(6):e0216697. doi:10.1371/journal.pone.0216697 PubMed DOI PMC

Lukes P, Zabrodsky M, Lukesova E, et al. . The role of NBI HDTV magnifying endoscopy in the prehistologic diagnosis of laryngeal papillomatosis and spinocellular cancer. Biomed Res Int. 2014;2014:285486. doi:10.1155/2014/285486 PubMed DOI PMC

Tjon Pian Gi REA, Halmos GB, van Hemel BM, et al. . Narrow band imaging is a new technique in visualization of recurrent respiratory papillomatosis. Laryngoscope. 2012;122(8):1826-1830. doi:10.1002/lary.23344 PubMed DOI

Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol. 2018;3(1):22-34. doi:10.1002/lio2.132 PubMed DOI PMC

Gazia F, Galletti B, Freni F, et al. . Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literature. Eur Rev Med Pharmacol Sci. 2020;24(2):956-962. doi:10.26355/eurrev_202001_20081 PubMed DOI

Sidell DR, Balakrishnan K, Best SR, et al. . Systemic bevacizumab for treatment of respiratory papillomatosis: international consensus statement. Laryngoscope. 2021;131(6):E1941-E1949. doi:10.1002/lary.29343 PubMed DOI PMC

Tkaczuk A, Trivedi S, Mody MD, et al. . Parenteral bevacizumab for the treatment of severe respiratory papillomatosis in an adult population. Laryngoscope. 2021;131(3):E921-E928. doi:10.1002/lary.29133 PubMed DOI

Allen CT, Lee S, Norberg SM, et al. . Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer. 2019;7(1):119. doi:10.1186/s40425-019-0603-3 PubMed DOI PMC

Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions: a review of the literature. Papillomavirus Res. 2019;8:100185. doi:10.1016/j.pvr.2019.100185 PubMed DOI PMC

Handisurya A, Schellenbacher C, Haitel A, Senger T, Kirnbauer R. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer. 2016;114(4):409-416. doi:10.1038/bjc.2015.462 PubMed DOI PMC

Buchinsky FJ, Ruszkay N, Valentino W, et al. . In RRP, serologic response to HPV is frequently absent and slow to develop. PLoS One. 2020;15(3):e0230106. doi:10.1371/journal.pone.0230106 PubMed DOI PMC

Tjon Pian Gi REA, San Giorgi MRM, Pawlita M, et al. . Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2016;273(10):3231-3236. doi:10.1007/s00405-016-4085-3 PubMed DOI PMC

Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group . Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509. doi:10.1016/S0140-6736(19)30298-3 PubMed DOI PMC

Falcaro M, Castañon A, Ndlela B, et al. . The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. doi:10.1016/S0140-6736(21)02178-4 PubMed DOI

Kjaer SK, Nygård M, Sundström K, et al. . Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Hum Vaccin Immunother. 2021;17(4):943-949. doi:10.1080/21645515.2020.1839292 PubMed DOI PMC

Lei J, Ploner A, Elfström KM, et al. . HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/NEJMoa1917338 PubMed DOI

Luostarinen T, Apter D, Dillner J, et al. . Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142(10):2186-2187. doi:10.1002/ijc.31231 PubMed DOI

Chaturvedi AK, Graubard BI, Broutian T, et al. . Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262-267. doi:10.1200/JCO.2017.75.0141 PubMed DOI PMC

Meites E, Stone L, Amiling R, et al. . Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States. Clin Infect Dis. 2021;73(5):885-890. doi:10.1093/cid/ciab171 PubMed DOI PMC

Novakovic D, Cheng ATL, Zurynski Y, et al. . A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208-212. doi:10.1093/infdis/jix498 PubMed DOI

Teutsch SM, Nunez CA, Morris A, et al. . Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2019. Commun Dis Intell (2018). 2020;44:44. doi:10.33321/cdi.2020.44.60 PubMed DOI

Bossart S, Imstepf V, Hunger RE, Seyed Jafari SM. Nonavalent human papillomavirus vaccination as a treatment for skin warts in immunosuppressed adults: a case series. Acta Derm Venereol. 2020;100(6):adv00078. doi:10.2340/00015555-3437 PubMed DOI PMC

Dion GR, Teng S, Boyd LR, et al. . Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review. JAMA Otolaryngol Head Neck Surg. 2017;143(6):614-622. doi:10.1001/jamaoto.2016.4736 PubMed DOI

Jentschke M, Kampers J, Becker J, Sibbertsen P, Hillemanns P. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine. 2020;38(41):6402-6409. doi:10.1016/j.vaccine.2020.07.055 PubMed DOI

Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891-898. doi:10.1093/cid/cir1036 PubMed DOI

Rosenberg T, Philipsen BB, Mehlum CS, et al. . Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis. 2019;219(7):1016-1025. doi:10.1093/infdis/jiy616 PubMed DOI

Tachezy R, Smahelova J, Kaspirkova J, Salakova M. Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PLoS One. 2013;8(11):e79156. doi:10.1371/journal.pone.0079156 PubMed DOI PMC

Hamsikova E, Smahelova J, Ludvikova V, et al. . The prevalence of HPV infections in HPV-vaccinated women from the general population. APMIS. 2017;125(6):585-595. doi:10.1111/apm.12677 PubMed DOI

Tachezy R, Hamsikova E, Valvoda J, et al. . Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: correlation between Southern blot hybridization, polymerase chain reaction, and serology. J Med Virol. 1994;42(1):52-59. doi:10.1002/jmv.1890420111 PubMed DOI

Durzyńska J, Błazejewska P, Szydłowski J, Goździcka-Józefiak A. Detection of anti-HPV11-L1 antibodies in immune sera from patients suffering from recurrent respiratory papillomatosis using ELISA. Viral Immunol. 2010;23(4):415-423. doi:10.1089/vim.2010.0014 PubMed DOI

Pinto LA, Dillner J, Beddows S, Unger ER. Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018;36(32 pt A):4792-4799. doi:10.1016/j.vaccine.2017.11.089 PubMed DOI PMC

Hamsikova E, Ludvikova V, Stasikova J, Tachezy R. Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic. Sex Transm Infect. 2013;89(2):133-137. doi:10.1136/sextrans-2012-050486 PubMed DOI PMC

Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009;200(7):1059-1067. doi:10.1086/604729 PubMed DOI

Newall AT, Brotherton JML, Quinn HE, et al. . Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis. 2008;46(11):1647-1655. doi:10.1086/587895 PubMed DOI

Abramson AL, Steinberg BM, Winkler B. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope. 1987;97(6):678-685. doi:10.1288/00005537-198706000-00005 PubMed DOI

Rautava J, Willberg J, Louvanto K, et al. . Prevalence, genotype distribution and persistence of human papillomavirus in oral mucosa of women: a six-year follow-up study. PLoS One. 2012;7(8):e42171. doi:10.1371/journal.pone.0042171 PubMed DOI PMC

Szydłowski J, Jonczyk-Potoczna K, Pucher B, et al. . Prevalence of human papillomavirus (HPV) in upper respiratory tract mucosa in a group of pre-school children. Ann Agric Environ Med. 2014;21(4):822-824. doi:10.5604/12321966.1129940 PubMed DOI

Bonagura VR, Hatam LJ, Rosenthal DW, et al. . Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS. 2010;118(6-7):455-470. doi:10.1111/j.1600-0463.2010.02617.x PubMed DOI PMC

Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis. Clin Exp Immunol. 2020;199(2):131-142. doi:10.1111/cei.13387 PubMed DOI PMC

Yiu Y, Fayson S, Smith H, Matrka L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2019;128(4):309-315. doi:10.1177/0003489418821695 PubMed DOI

Off-label drugs in laryngology- what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01375868